Video

QUAZAR: Oral Azacitidine Maintenance in AML

Transcript:

Related Videos
Sujith Samarasinghe, MD
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Michael R. Grunwald, MD, FACP
Shella Saint Fleur-Lominy, MD, PhD
Manali Kamdar, MD
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
Related Content
Ruben A. Mesa, MD, FACP, of Atrium Health Levine Cancer Institute
June 17th 2024

Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Talha Munir, MBChB, PhD, Leeds Teaching Hospital NHS Trust
June 15th 2024

Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

The FDA has approved blinatumomab (Blincyto) for the treatment of adult and pediatric patients aged 1 month or older who have CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia in the consolidation phase, irrespective of measurable residual disease status.
June 14th 2024

FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase

Radhika Bansal, MBBS
June 14th 2024

CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL